China's first bio-safety level P3 bio-pharmaceutical production workshop for human use was recently completed and delivered.

With an annual output of 100 million doses, the workshop is expected to be the largest COVID-19 vaccine manufacturing workshop in the world when it starts mass production.

Contracted by the Fourth Construction Co., Ltd. of China Electronics System Engineering, a subsidiary of China Electronic Corporation (CEC), the project is also the first in the vaccine production field in China at the P3 bio-safety level in prevention and control of major epidemics.

During construction, the material purchasing, engineering plans, construction procedures as well as pandemic prevention and control were scientifically arranged in advance.

The company was also responsible for construction of several of the first inactivated virus vaccine production workshops with a high level of bio-safety in China after the COVID-19 pandemic broke out.

More than 80 percent of the top 20 projects of international bio-pharmaceutical enterprises and over a half of the domestic ones were undertaken by the company.

In addition, more than 80 bio-pharmaceutical projects related to research and production of vaccines, blood products, monoclonal antibodies, cell therapy and insulin, already completed or still in progress, are contracted by Fourth Construction Co., Ltd. of China Electronics System Engineering.

Fourth Construction Co., Ltd. of China Electronics System Engineering is responsible for construction of China's first P3 bio-safety level pharmaceutical production workshop for human use. [Photo/sasac.gov.cn]

From:State-owned Assets Supervision and Administration Commission of the State Council